KORU Medical Systems just watched its stock slide 13.8% in a single session, even as the business finally put a small profit on the board. That clash between price and progress is the real story today.

Coming into this report, the stock had already been under pressure over 7 days and 30 days. Yet KORU delivered record Q2 revenue of US$12.0m and turned a modest net income of US$0.3m after a string of quarterly losses. The market is trading the guidance trim and near term worries. The results point to a different conversation about earnings quality and momentum that investors now have to weigh.

Is KORU Medical Systems now mispriced after a 13.8% drop when its Q2 2026 profit and revenue of US$12.0m hit the tape, or is the premium P/S multiple a warning sign? Compare the current market price against our detailed valuation analysis for KORU Medical Systems

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs. Q2 2025: US$12.05m vs. US$10.19m (up about 18%)
• Net Income, Q2 2026 vs. Q2 2025: Profit of US$0.25m vs. loss of US$0.21m (moved from loss to profit)
• Basic EPS, Q2 2026 vs. Q2 2025: US$0.0055 per share vs. a loss of US$0.0045 per share (moved from loss to profit on a per share basis)
• Gross Margin, Q2 2026 vs. Q2 2025: 65.1% vs. 63.5% (modest margin improvement)

Prefer clean charts instead of another wall of earnings tables and footnotes? Get a full visual read on KORU Medical Systems, including how analysts are framing the story around the latest results, in our company report for KORU Medical Systems.

KORU bull case: core Ig engine and margins on test

Bulls argue KORU Medical Systems is turning its core Ig franchise and platform strategy into a durable earnings engine. This quarter does give them some concrete wins. Record Q2 revenue of US$12.0m, 18% above last year, lines up with the story that the installed base of roughly 60,000 home Ig patients can support steady consumables demand. Domestic Ig revenue of US$8.0m grew faster than underlying SCIg, which points to share gains rather than just market lift. Gross margin at 65.1%, above both last year and the updated 62% to 64% full year guide, shows the supplier contract and productivity work are flowing through. Positive net income and positive adjusted EBITDA, while modest, show the operating model can generate cash without heavy cost cuts. The bull case that KORU can be sustainably profitable now has at least an initial proof point.

KORU bear case: growth timing, oncology and reliance on ramp

Bears focus on growth durability, concentration risk and execution on new indications. The trimmed full year revenue guide to US$47.5m to US$48.5m, framed as timing on international non tender markets, is a clear miss against the faster ramp narrative. International revenue of US$3.5m grew quickly but management explicitly warned that some launches are slower than originally assumed, which feeds concerns about reliance on prefilled syringe conversions. Pharma services revenue of US$0.6m declined 35% year on year, underlining how lumpy that pipeline can be even as management leans on collaborations in Ig and non Ig drugs as a growth pillar. The decision to withdraw the Phesgo oncology 510(k) in the U.S. and rethink the approach keeps the oncology consumables opportunity in the future rather than delivering revenue today. With the stock down 13.8% on the day, the market reaction suggests these execution risks are front of mind.

With KORU Medical Systems still unprofitable on trailing metrics and trading on a premium P/S multiple, the key question is whether the balance sheet can comfortably fund that forecasted ramp. Check the full liquidity and cash runway breakdown in our financial health analysis of KORU Medical Systems stock.

Stay Ahead With Simply Wall St

If the 13.8% drop on KORU Medical Systems after its first quarterly profit has your attention, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and spot an entry point that fits your plan. Once you own KORU Medical Systems or other holdings, use the Portfolio Command Center to cut through market noise and keep on top of only the updates that really matter to your investments. For longer term decisions, tap into crowd wisdom through the Community so you can see how other investors are interpreting new information and catalysts. By surfacing hidden risks and potential triggers early, Simply Wall St helps you stay ahead of the market and make more confident moves.

Seeking Alternatives Beyond KORU Medical Systems

Fresh ideas move first. Stocks can go from quiet to breakout quickly, and the best entry points often pass before the crowd catches on, so act promptly and thoughtfully.

• Spot cash rich companies with room to fund growth and stay resilient by scanning the curated list of solid balance sheet and fundamentals stocks (49 results) before those balance sheets reflect all available information.
• Consider structural themes with lower volatility by reviewing 77 resilient stocks with low risk scores while these steady compounders remain less widely followed.
• Explore income-focused opportunities that may support long term plans by checking 9 dividend fortresses before yields adjust and valuations change.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.